Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Up 1,180.0% in March

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) saw a significant growth in short interest in March. As of March 31st, there was short interest totalling 6,400 shares, a growth of 1,180.0% from the March 15th total of 500 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 866,800 shares, the short-interest ratio is currently 0.0 days.

Provectus Biopharmaceuticals Price Performance

Shares of Provectus Biopharmaceuticals stock traded up $0.00 on Monday, hitting $0.10. The company’s stock had a trading volume of 31,218 shares, compared to its average volume of 227,284. Provectus Biopharmaceuticals has a 1 year low of $0.04 and a 1 year high of $0.20. The firm has a fifty day moving average price of $0.10 and a 200-day moving average price of $0.11.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.